ADC Nanoaggregate Composition for Heterogeneous Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges in delivering drugs effectively and improving tissue specificity and cytotoxicity, with only a limited number of ADCs receiving market approval despite significant research and development efforts.
Innovation Solution
A pharmaceutical composition comprising a targeting bioactive agent (TBA) with binding affinity to a target molecule, a payload bioactive agent (PBA) covalently linked to the TBA, and a polymer such as polyoxazoline or polyethylene glycol, forming nanoaggregates that enhance targeted drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ADCs are used for targeted drug delivery, then tumor cells can be targeted with cytotoxic drugs, but the therapeutic efficacy and tissue specificity are limited
Solution Approach 1:
The patent combines multiple components into a composite nanoaggregate structure: targeting bioactive agents (such as antibodies) for specific tumor cell recognition, payload bioactive agents (cytotoxic drugs) for killing tumor cells, and polymers (polyoxazoline or polyethylene glycol) for stability and controlled release. This composite approach enables simultaneous achievement of high therapeutic efficacy through cytotoxic drug delivery and improved tissue specificity through targeted binding, resolving the contradiction between these two parameters.
2Reliability
If more ADCs are developed to improve treatment options, then cancer therapy efficacy can be enhanced, but the complexity of design and development increases
Solution Approach 1:
The patent creates a universal nanocomposition platform with a standardized structure comprising targeting bioactive agents, payload bioactive agents, and polymer components. This multi-functional platform can be adapted to target different cancer types by simply changing the targeting agent (e.g., different antibodies for different tumor antigens) while maintaining the same core delivery mechanism. This universality reduces design complexity compared to developing entirely new ADCs for each cancer type, while still enabling enhanced cancer therapy efficacy through optimized drug delivery.
3Reliability
If cytotoxic drugs are delivered systemically to treat cancer, then tumor cells can be reached, but tissue specificity is reduced and off-target effects increase
Solution Approach 1:
The patent implements local quality by concentrating the cytotoxic payload within nanoaggregates that are specifically targeted to tumor cells. The polymer component (polyoxazoline or polyethylene glycol) provides localized controlled release of the cytotoxic drug at the tumor site through mechanisms such as pH-responsive or enzymatic degradation. This ensures high tumor cell killing efficacy where the nanoaggregates accumulate, while minimizing off-target cytotoxicity because the cytotoxic drug remains sequestered within the nanoaggregate structure during circulation and only releases locally at the target site.
Data Source
AI summary
This disclosure is directed to a pharmaceutical composition for treating or preventing a disease. The pharmaceutical composition can comprise a targeting bioactive agent (TBA); a payload bioactive agent (PBA) covalently linked to the targeting bioactive agent (TBA) directly or indirectly; and, optionally, a polymer forming nanoaggregates. The pharmaceutical composition can comprise Ag+ tumor cytotoxicity to tumor cells having a tumor antigen (Ag+ tumor cells) and Ag− tumor cytotoxicity to tumor cells free from a tumor antigen (Ag− tumor cells). The pharmaceutical composition can be an antibody-drug conjugate (ADC) for treating cancers having tumor antigen positive (Ag+) tumor cells, tumor antigen negative (Ag−) tumor cells, or heterogenous cancers having both tumor antigen positive (Ag+) tumor cells and tumor antigen negative (Ag−) tumor cells.